Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats
André P. Lourenço, Roberto Roncon-Albuquerque, Jr., Carmen Brás-Silva, Bernardo Faria, Joris Wieland, Tiago Henriques-Coelho, Jorge Correia-Pinto and Adelino F. Leite-Moreira

This article cites 38 articles, 24 of which you can access for free at:
http://ajpheart.physiology.org/content/291/4/H1587.full#ref-list-1

This article has been cited by 14 other HighWire-hosted articles:
http://ajpheart.physiology.org/content/291/4/H1587#cited-by

Updated information and services including high resolution figures, can be found at:
http://ajpheart.physiology.org/content/291/4/H1587.full

Additional material and information about American Journal of Physiology - Heart and Circulatory Physiology can be found at:
http://www.the-aps.org/publications/ajpheart

This information is current as of July 16, 2013.
Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats

André P. Lourenço, Roberto Roncon-Albuquerque, Jr., Carmen Brás-Silva, Bernardo Faria, Joris Wieland, Tiago Henriques-Coelho, Jorge Correia-Pinto, and Adelino F. Leite-Moreira

Department of Physiology, Faculty of Medicine, University of Porto, Porto, Portugal

Submitted 20 September 2005; accepted in final form 23 April 2006

Am J Physiol Heart Circ Physiol 291: H1587–H1594, 2006. First published May 5, 2006; doi:10.1152/ajpheart.01004.2005.—In monocrotaline (MCT)-induced pulmonary hypertension (PH), only the right ventricle (RV) endures overload, but both ventricles are exposed to enhanced neuroendocrine stimulation. To assess whether in long-standing PH the left ventricular (LV) myocardium molecular/contractile phenotype can be disturbed, we evaluated myocardial function, histology, and gene expression of autocrine/paracrine systems in rats with severe PH 6 wk after subcutaneous injection of 60 mg/kg MCT. The overloaded RV underwent myocardial hypertrophy (P < 0.001) and fibrosis (P = 0.014) as well as increased expression of angiotensin-converting enzyme (ACE) (8-fold; P < 0.001), endothelin-1 (ET-1) (6-fold; P < 0.001), and type B natriuretic peptide (BNP) (15-fold; P < 0.001). Despite the similar upregulation of ET-1 (8-fold; P < 0.001) and overexpression of ACE (4-fold; P < 0.001) without BNP elevation, the nonoverloaded LV myocardium was neither hypertrophic nor fibrotic. LV indexes of contractility (P < 0.001) and relaxation (P = 0.03) were abnormal, however, and LV muscle strips from MCT-treated compared with sham rats presented negative (P = 0.003) force-frequency relationships (FFR). Despite higher ET-1 production, BQ-123 (ETα antagonist) did not alter LV MCT-treated muscle strip contractility distinctly (P = 0.005) from the negative inotropic effect exerted on shams. Chronic daily therapy with 250 mg/kg bosentan (dual endothelin receptor antagonist) after MCT injection not only attenuated RV hypertrophy and local neuroendocrine activation but also completely reverted FFR of LV muscle strips to positive values. In conclusion, the LV myocardium is altered in advanced MCT-induced PH, undergoing neuroendocrine activation and contractile dysfunction in the absence of hypertrophy or fibrosis. Neuroendocrine mediators, particularly ET-1, may participate in this functional deterioration. Neuroendocrine stimulation, only the right ventricle (RV) experiences increased biomechanical load (18). The role of overload as a cause of myocardial hypertrophy, molecular remodeling, and dysfunction in the progression to heart failure (HF) has been substantially underscored in these PH experimental models (16, 18, 30, 32), since most of the changes are restricted to the hypertrophied RV. Yet, some modifications also have been identified in the left ventricular (LV) genome and proteome of rats with hypoxia-induced (32) and monocrotaline (MCT)-induced PH (30). Studying the normally loaded LV of PH rats may be very helpful to ascertain the actions of neuroendocrine systems per se. Curiously, neuroendocrine actions have been considerably highlighted in models of experimental PH. Particularly, endothelin-1 (ET-1) contributes to the progression of cardiopulmonary alterations in MCT-induced PH (24), and chronic therapy with either a selective ETα or a nonselective ETα/β receptor antagonist improves the survival and ameliorates pulmonary blood flow and RV hemodynamics but, interestingly, also reverses dysfunctional LV contractility and relaxation in MCT-treated rats (14). The present study was undertaken to characterize the molecular and contractile phenotype of the LV myocardium of MCT-treated rats with advanced PH. After hemodynamic evaluation and morphometric characterization of PH rats 6 wk after MCT injection, we assessed in both ventricles histological features such as myocardial fibrosis and myocyte diameters, and we quantified mRNA levels of genes previously implicated in autocrine/paracrine activation during HF progression such as ET-1, angiotensin-converting enzyme (ACE), type B natriuretic peptide (BNP), angiotensinogen, and aldosterone synthase. We further evaluated the contractile phenotype of the LV myocardium of MCT rats in vitro, performing force-frequency relationships (FFR) in LV muscle strips. Because a considerable increase in myocardial ET-1 mRNA levels was observed, we assessed to greater extent both ET-1 myocardial production by immunostaining and its myocardial actions by acutely blocking ETα receptors with BQ-123 in LV muscle strips and chronically treating MCT-injected rats with the dual endothelin receptor antagonist bosentan.

METHODS

Animal model. Seven-week-old male Wistar rats (Charles-River, Barcelona, Spain) were housed in groups of five per cage with a controlled environment under a 12:12-h light-dark cycle at a room temperature of 22°C. Rats randomly received either a subcutaneous injection of MCT (60 mg/kg; Sigma Chemical, St. Louis, MO) or an...
equal volume of vehicle and were studied 36–40 days (6 wk) after injection. Previously, we (8) observed that rats develop PH and RV hypertrophy, without overt HF, 22–25 days after subcutaneous injection of 60 mg/kg MCT. Knowing that the time elapsed from injection of MCT to the development of severe hypertrophy and HF is strongly dependent on the dose in relation to the age of the animals studied (35), we decided to study rats 6 wk after injection. Because MCT-treated rats consume significantly less food, the amount of chow fed to sham rats was restricted to the quantity consumed by MCT-treated rats during the previous day, to avoid noticeable differences in nutritional state (18). A group of randomly selected MCT-treated rats underwent chronic daily therapy with 250 mg/kg bosentan (kindly provided by Actelion Pharmaceuticals) administered by gavage (25 mg/ml in 5% gum arabic) starting 2 days after MCT injection and ending 48 h before experimentation. Experiments were subjected to the Portuguese law on animal welfare and conform to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996), having been performed at the Faculty of Medicine of the University of Porto (Porto, Portugal), which is a governmental Institution granted to perform animal research.

**Hemodynamic assessment.** As previously reported (8), animals (MCT treated and sham, n = 7 each) were anesthetized with an intraperitoneal injection of pentobarbital sodium (6 mg/100 mg), mechanically ventilated (Harvard Rodent Ventilator model 683), and compensated for per operative fluid losses. The pericardium was widely opened after a median sternotomy was performed. A silk thread was passed around the ascending aorta to transiently occlude it during the experimental protocol. RV and LV pressures were measured with high-fidelity micromanometers (Millar Instruments SPR-407) inserted into the ventricular cavities. LV septal-lateral diameter was assessed with a sonomicrometer amplifier (Triton Electronics, San Diego, CA) after the implantation of ultrasonic crystals in the interventricular septum and epicardial surface of the LV free wall as previously described (3). After stabilization for 15 min, basal RV and LV peak rate of pressure rise (dP/dt_max), end-diastolic pressure (EDP), peak systolic pressure (SP), LV end-diastolic dimension (LVEDD), LV peak rate of pressure rise (dP/dt_max), end-diastolic pressure (EDP), peak systolic pressure (SP), LV end-diastolic dimension (LVEDD), and peak systolic LV isovolumetric pressure (LVp_iso) were recorded. Relaxation rate was estimated with the time constant t by fitting the isovolumetric pressure fall to a monoeponential function, as previously described (20). Parameters were sampled with a frequency of 1,000 Hz. Recordings were made with respiration suspended at end expiration. An ECG lead (II) was recorded throughout. RV and septum plus LV free wall wet weights were determined at the end of the experimental protocol after anesthetic overdose. Transmural LV and RV free wall samples were snap frozen in liquid nitrogen and stored at −80°C for subsequent molecular analyses.

**Intact muscle strip preparations.** Briefly, rats were anesthetized with intraperitoneal ketamine-xylazine (50 mg/kg and 8 mg/kg, respectively), a left thoracotomy was performed, and beating hearts were quickly excised and immersed in modified Krebs-Ringer (KR) solution containing (in mM) 93 NaCl, 5 KCl, 1 MgSO4, 1.2 KH2PO4, 10 glucose, 1.25 CaCl2, 20 NaHCO3, 1 Na2HPO4, 20 NaC2H3O2, and 5 U/l insulin with cardioplegic 2,3-butanediol monoxide (BDM; 2.5%) equilibrated with 95% O2-5% CO2. Thin muscle strips (cross-sectional diameter < 400 μm) were carefully isolated from LV papillary muscles under a dissecting microscope (Leica Wilde M651), mounted vertically in a 10-ml Plexiglas organ bath, and attached to an electromagnetic length–tension transducer (University of Antwerp, Antwerp, Belgium). Twenty minutes later, bathing solutions were replaced by modified KR solution without BDM. Preload was estimated according to muscle dimensions, and electrical stimulation was set 10% above threshold and at a frequency of 0.5 Hz. Muscles were allowed to stabilize, and the experimental protocol was begun once three comparable basal isotonic and isometric contractions were separately recorded with an interval of at least 10 min. Temperature was kept at 35°C and pH at 7.4 throughout the experimental protocol. In one set of LV muscle strips from sham (n = 9), MCT (n = 9) and MCT + bosentan rats (n = 8), isometric FFR were obtained after an initial period of contraction at 0.5 Hz by stepping up the frequency of stimulation at 3-min intervals and sequentially recording five contractions at 1, 2, 3, 4, and 5 Hz. In another set of LV sham (n = 7), MCT (n = 7), and MCT + bosentan (n = 6) muscle strips, the effects of ETA antagonism were evaluated by recording several isometric and isometric contractions before and 20–30 min after a concentration of 1 μM of the selective ETA antagonist BQ-123 (Sigma Chemical) was added to the bath. Developed tension (mN/mm2) was computed, using software, from the weight and length of the muscle strip by assuming an ellipsoid shape. Muscle maximum cross-sectional diameters measured with a microscope (Leica DM4000B) were similar (P = 0.15) in sham (25 ± 24 μm), MCT (280 ± 27 μm), and MCT + bosentan muscle strips (305 ± 41 μm), excluding the possibility that differences in muscle strip dimensions had an impact on contractile function.

**Histology and immunohistochemistry.** Transverse 4-μm-thick sections of paraffin-embedded, formalin-fixed specimens encompassing the RV, interventricular septum, and LV free wall were stained and photographed with a digital camera (Leica DFC320) in a group of additional sham (n = 4) and MCT rats (n = 4). The shortest diameter of 50 transversally cut, randomly selected cardiomyocytes from the RV, septum, and LV free wall myocardium was measured with image analyzer software (Leica IM-1000) at the level of the nucleus in hematoxylin-eosin-stained sections. Two independent, blinded observers ranked histological sections stained with Masson’s trichrome for collagen as having no fibrosis (grade 0); a localized small amount of fibrosis (grade 1); mild, patchy fibrosis (grade 2); moderate, diffuse fibrosis (grade 3); or severe, diffuse fibrosis (grade 4). Immunohistochemical staining of ETA was performed with a 1:800 dilution of rabbit ET-1 antiserum (T-4050; Peninsula Laboratories) at 4°C for 16 h after initial incubation with 0.3% H2O2 and blocking solution (TR-004-HD; Labvision) at room temperature. The sample was then sequentially exposed at room temperature to biotinylated goat anti-rabbit (TR-004-HD; Labvision) for 15 min, to streptavidin peroxidase (TR-004-HD; Labvision) for 15 min, and, finally, to 4% 3,3-diaminobenzidine (TR-004-HD; Labvision) for 10 min. Counterstaining was performed with hematoxylin.

**Relative quantification of mRNA.** Two-step real-time RT-PCR was performed as previously described (8). Briefly, after total mRNA extraction (no. 74124; Qiagen), standard curves were obtained for each gene correlating (R ≥ 0.98) the mRNA quantities in graded dilutions of a rat cardiac tissue sample with the respective threshold cycles (second derivative maximum method). Equal amounts of mRNA from every sample underwent three separate two-step real-time RT-PCR experiments for each gene, using SYBR green as marker (no. 204143; Qiagen). GAPDH was used as internal control, because its mRNA levels were similar in the studied groups. Results are relative to the mean obtained for the sham group (set as arbitrary unit) and normalized for GAPDH. Specific PCR primer pairs for the studied genes are presented in Table 1.

**Statistical analysis.** Data are expressed as means ± SE. Statistical analysis used a two-way ANOVA to compare cardiomyocyte hypertrophy data; a repeated-measures two-way ANOVA followed by Holm-Sidak’s method for multiple comparisons was applied to data from FFR in intact muscle strip preparations; and Fisher’s exact test was used to evaluate myocardial fibrosis after categories were grouped. One-way ANOVA and Student’s t-test were used to compare other results as indicated. Statistical significance was set at a two-tailed value of P < 0.05.

**RESULTS**

Rats were studied 6 wk after injection, at which point the mortality was null in sham rats but ~85% in MCT and 50% in MCT + bosentan rats. All MCT rats presented clinical signs of overt HF, namely, lethargy, labored breathing, cachexia, vein
and liver engorgement, pleural effusion, and ascites. Although MCT + bosentan rats also presented these clinical signs, they distinguished themselves from MCT rats because they showed less lethargy on a qualitative evaluation. The body weight (BW) of sham rats was similar to the BW of MCT and MCT + bosentan rats (266 ± 16, 240 ± 13, and 250 ± 12 g, respectively; \( P = 0.37 \)).

**Cardiac hemodynamics, morphometry, and histology.** The hemodynamic features of the experimental groups are summarized in Table 2. MCT rats showed a marked increase in RVSP compared with sham rats (\( P < 0.001 \)). This was accompanied by other modifications in hemodynamic profile, such as increased values of RV dP/dt max (\( P = 0.014 \)), \( \tau (P < 0.001) \), and RVEDP (\( P = 0.003 \)), but also by morphometric (Fig. 1) and histological changes (Table 3 and Figs. 1C and 2), such as increased ratio of RV weight to BW (\( P < 0.001 \)), increased RV cardiomyocyte diameters (\( P < 0.001 \)), and significantly higher myocardial fibrosis (\( P = 0.014 \)). In contrast to the RV myocardium, the grade of myocardial fibrosis observed in the LV of MCT rats did not differ from that of sham rats (Table 3 and Fig. 2), and despite the tendency toward an increase in the ratio of LV and septum as a whole to BW (Fig. 1), only septal (\( P < 0.001 \)) and not LV free wall cardiomyocytes presented increased diameters (Fig. 1C). Likewise, the LV filling pressures as estimated by LVEDP and LVEDD were unaltered. The maximum developed pressures (LVSP), however, were reduced (\( P < 0.001 \)) as well as the indexes of contractility, dP/dt max (\( P < 0.001 \)) and LVP isov (\( P < 0.001 \)), respectively.

**Table 1. Primers used in mRNA quantification**

<table>
<thead>
<tr>
<th>Gene</th>
<th>5’ → 3’ Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>fw: TGG CCT TCC GAG AAG GGG AGG AC</td>
</tr>
<tr>
<td>rev: CCA AGG GGC TGT CTA ACA</td>
<td></td>
</tr>
<tr>
<td>ET-1</td>
<td>fw: CCA GGG AGG AGG AGG AGG AGG AGG AGG</td>
</tr>
<tr>
<td>rev: CAG GGC TGC TTA TTA TTA</td>
<td></td>
</tr>
<tr>
<td>ACE</td>
<td>fw: GGA GGC CAG CAG GGT CCA CTA CAC</td>
</tr>
<tr>
<td>rev: GAC CTC GCC ATT CCG CTG ATT CT</td>
<td></td>
</tr>
<tr>
<td>BNP</td>
<td>fw: GGA CCA AGG CCC TAC AAA AGA</td>
</tr>
<tr>
<td>rev: CAG AGG TGG GGA AAG AAG AG</td>
<td></td>
</tr>
<tr>
<td>Angiotensinogen</td>
<td>fw: CGG ACA GCA CCC TAT TTT TTA ACA</td>
</tr>
<tr>
<td>rev: GAG GCC GAC TGG GGC TGG AT</td>
<td></td>
</tr>
<tr>
<td>Aldosterone synthase</td>
<td>fw: AAT GGC GCT TCA ACC GAC TG</td>
</tr>
<tr>
<td>rev: GAG CAT TCT GAC GCA CCT TCT TTT</td>
<td></td>
</tr>
<tr>
<td>HIF-1α</td>
<td>fw: CTA ACA AGG GGG GGG AGG AC</td>
</tr>
<tr>
<td>rev: TCA TAG GGG GTT TCT TCT TCT</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2. Hemodynamic data**

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>MCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>( n )</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>RV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVSP, mmHg</td>
<td>20.8±1.3</td>
<td>51.4±4.1 *</td>
</tr>
<tr>
<td>RVEDP, mmHg</td>
<td>0.9±0.4</td>
<td>3.9±0.7 *</td>
</tr>
<tr>
<td>dP/dt max, mmHg/s</td>
<td>936±72</td>
<td>1,411±173 *</td>
</tr>
<tr>
<td>( \tau ), ms</td>
<td>7.8±0.7</td>
<td>37.8±2.3 *</td>
</tr>
<tr>
<td>LV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVSP, mmHg</td>
<td>95.1±2.5</td>
<td>60.2±3.5 *</td>
</tr>
<tr>
<td>LVEDP, mmHg</td>
<td>6.7±0.6</td>
<td>7.8±0.9</td>
</tr>
<tr>
<td>LVEDD, mm</td>
<td>6.4±0.8</td>
<td>5.4±0.8</td>
</tr>
<tr>
<td>dP/dt max, mmHg/s</td>
<td>4,749±323</td>
<td>2,205±272 *</td>
</tr>
<tr>
<td>LVP max, mmHg</td>
<td>193.1±7.2</td>
<td>131.5±6.6 *</td>
</tr>
<tr>
<td>( \tau ), ms</td>
<td>21.5±1.7</td>
<td>26.9±2.2 *</td>
</tr>
</tbody>
</table>

Values are means ± SE. MCT, monocrotaline-treated rats; RV, right ventricle; RVSP, right ventricular systolic pressure; RVEDP, right ventricular end-diastolic pressure; LV, left ventricle; LVPSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; LVEDD, left ventricular end-diastolic dimension; dP/dt max, peak rate of ventricular pressure rise; LVP isov, peak systolic isovolumetric pressure; \( \tau \), time constant of isovolumetric relaxation. Comparisons were performed using Student’s t-test. *\( P < 0.05 \) vs. sham.

**Fig. 1.** Hypertrophic response to monocrotaline (MCT)-induced pulmonary hypertension. A: right ventricle weight (RVW)-to-body weight (BW) ratio. B: left ventricle free wall weight + interventricular septum weight (LVW+SW)-to-BW ratio. Student’s t-test was used to compare sham (\( n = 7 \)) and MCT-treated rats (\( n = 7 \)). RVW/BW was significantly increased in MCT rats (*\( P < 0.001 \)). C: LV free wall, interventricular septum, and RV free wall cardiomyocyte diameters from sham (\( n = 4 \)) and MCT-treated rats (\( n = 4 \)). Two-way ANOVA and Holm-Sidak’s method for multiple comparisons were used in the statistical analysis. Septal cardiomyocytes of MCT-treated rats were significantly larger than cardiomyocytes from sham rats and from the LV of MCT-treated rats (*\( P < 0.001 \)), yet the largest cardiomyocytes were those from the RV of MCT-treated rats, which were significantly larger than the corresponding septal myocytes (†\( P < 0.001 \)).

**Table 3. Myocardial fibrosis**

<table>
<thead>
<tr>
<th>Fibrosis</th>
<th>Sham</th>
<th>MCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade</td>
<td>RV</td>
<td>LV</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Fibrosis grades: 0, no fibrosis; 1, localized small amount of fibrosis; 2, mild patchy fibrosis; 3, moderate, diffuse fibrosis; and 4, severe, diffuse fibrosis. P value was calculated using Fisher’s exact test after grouping categories (grades 0 and 1 in sham rat RV vs. grades 2 and 3 in MCT-treated rat RV). *\( P = 0.014 \) vs. sham RV (\( n = 4 \) for sham and MCT).
whereas the relaxation time constant $\tau$ was increased ($P = 0.03$) in the LV of MCT rats. The heart rate of MCT rats was significantly decreased as well (sham = 272 ± 14 beats/min vs. MCT = 200 ± 17 beats/min; $P = 0.008$). Chronic therapy with bosentan after MCT injection attenuated RV hypertrophy ($P < 0.001$) as assessed by a reduction in the ratio of RV free wall to LV free wall plus interventricular septum weight (Fig. 3).

**Autocrine/paracrine activation.** Changes in the expression of genes involved in autocrine/paracrine activation during the progression to heart failure in MCT-treated rats with and without subsequent chronic therapy with bosentan are summarized in Fig. 4. ACE and ET-1 mRNA levels were increased in both the RV and the LV free wall myocardium of MCT rats ($P < 0.01$), whereas BNP mRNA overexpression was restricted to the RV myocardium ($P < 0.001$). The RV myocardium of MCT rats also presented a more pronounced upregulation of the ACE gene ($P = 0.03$), but the increase in ET-1 mRNA levels was not different between ventricles ($P = 0.694$). The indiscriminate increase in ET-1 production was

![Fig. 2. Representative photomicrographs ($\times200$) of Masson’s trichrome-stained sections from sham and MTC-treated rats for evaluation of myocardial fibrosis. A: sham rat RV. B: MCT-treated rat RV. C: sham rat LV. D: MCT-treated rat LV. Note the increased fibrosis in the RV of MCT-treated rats.](http://ajpheart.physiology.org/)

![Fig. 3. RVW-to-LVW+SW ratios in sham ($n = 7$) and MCT-treated rats with (MCT+bosentan, $n = 7$) and without subsequent chronic daily therapy with 250 mg/kg bosentan by gavage (MCT, $n = 7$). As evaluated with one-way ANOVA, $^*P < 0.001$ vs. sham and $^\dagger P < 0.001$ vs. MCT.](http://ajpheart.physiology.org/)

![Fig. 4. LV (left) and RV (right) mRNA levels of angiotensin-converting enzyme (ACE), endothelin-1 (ET-1), and type-B natriuretic peptide (BNP) in rats with MTC-induced pulmonary hypertension with (MCT, $n = 7$) and without chronic daily therapy with 250 mg/kg bosentan by gavage (MCT+bosentan, $n = 7$). Results are expressed as arbitrary units after normalization for GAPDH. The arbitrary unit was set as the average value of the sham group and is presented as a reference line. ACE and ET-1 gene expression were increased in both ventricles of MCT compared with sham ($n = 7$) rats ($^*P < 0.01$, as evaluated with one-way ANOVA), whereas MCT+bosentan showed no significant differences in mRNA levels from sham mRNA levels. In MCT and MCT+bosentan, BNP was only overexpressed in the RV ($^*P < 0.001$, as evaluated with one-way ANOVA). ACE and BNP were significantly more upregulated in the RV than in the LV of MCT ($^\dagger P = 0.03$ and $P = 0.002$ as evaluated with Student’s t-test, respectively).](http://ajpheart.physiology.org/)
confirmed by a striking immunostaining of cardiomyocytes from both the LV and RV myocardium of MCT rats, whereas the staining in sham rat myocardium was found almost exclusively in vascular endothelium (Fig. 5). The MCT + bosentan group showed no significant differences in the gene expression of ACE and ET-1 in both the RV and the LV compared with either the sham or MCT group, indicating an intermediate level of gene expression (Fig. 4). RV BNP mRNA levels were significantly increased compared with sham rats \((P < 0.001)\), and although their increase was of lower magnitude, it did not differ from that of MCT rats.

No significant differences were observed in the RV and LV expression of aldosterone synthase \((1.2 \pm 0.7 \text{ vs. } 1.0 \pm 0.2, P = 0.4, \text{ and } 1.7 \pm 0.8 \text{ vs. } 1.0 \pm 0.2, P = 0.22, \text{ respectively})\) or angiotensinogen \((1.2 \pm 0.3 \text{ vs. } 1.0 \pm 0.1, P = 0.29, \text{ and } 1.3 \pm 0.4 \text{ vs. } 1.0 \pm 0.1, P = 0.22, \text{ respectively})\) in MCT-treated rats compared with sham rats. The gene expression of transcription factor HIF-1\(α\) was studied in the LV of MCT-treated rats to assess a possible role of hypoxia on neuroendocrine activation. No differences were observed (sham = 1.0 ± 0.1 arbitrary units vs. MCT = 1.3 ± 0.2 arbitrary units; \(P = 0.22\)).

Contractile properties of intact LV muscle strips. Isometrically contracting muscle strips from sham and MCT + bosentan LV showed a steady increase in developed tension between 1 and 5 Hz, indicating positive FFR, whereas MCT LV muscle strips responded in the opposite way \((P < 0.001)\), presenting overall negative FFR (Fig. 6). Baseline force development was not different \((P = 0.16)\) among the three groups and averaged 2.2 ± 0.4 mN/mm². Adding the selective ET\(A\) antagonist BQ-123 to in vitro contracting LV intact muscle strips induced different responses \((P = 0.005)\) in sham compared with MCT and MCT + bosentan muscle strips: a negative inotropic effect was elicited in sham muscle strips \((P < 0.032)\), whereas the tension developed by MCT and MCT + bosentan muscle strips remained unaltered (Fig. 7).

**DISCUSSION**

We have demonstrated that the LV myocardium of MCT-treated rats with long-standing PH presents autocrine/paracrine system activation in the absence of a direct hemodynamic stress, and although myocardial hypertrophy and fibrosis are not observed, its contractile phenotype is disturbed.

MCT-treated rats developed PH, RV myocardial hypertrophy, and fibrosis. A higher expression of genes that take part in the processes of molecular remodeling was observed in the chronically overloaded RV myocardium but also in the LV myocardium. Despite the pronounced upregulation of ACE and
Reduction of LVSP in MCT-treated rats was accompanied by disturbed hemodynamic contractility and relaxation indexes, as previously described (14). Albeit, LV fibrosis and atrophy were ruled out, and even though invasive hemodynamic indexes were obtained with a widely open pericardium, thus reducing ventricular interdependence (33), the majority of studies carried out in PH patients (22, 29) attribute LV dysfunction fundamentally to ventricular interdependence and impaired LV filling (22) or geometric modifications (4). This is supported by the development of septal hypertrophy in our group of MCT-treated rats but not by the evidence of unaltered LVEDP and LVEDD. Likewise, conserved LV volumes have been reported despite LV functional deterioration in PH (7). However, it should be stressed that because we evaluated LV dimensions through a simple septal-lateral diameter, which does not allow a thorough evaluation of LV volume, and therefore an accurate determination of LV preload, preload-dependent indexes such as dP/dt max and peak isovolumic pressures are insufficient to definitely establish impaired contractility.

To further elucidate the myocardial contractile phenotype of the LV in MCT-treated rats, safeguarding the possibility that our findings were not due to ventricular interdependence, we conducted experiments with LV myocardium on intact muscle strip preparations. The FFR is an important intrinsic regulatory mechanism of cardiac contractility; normal myocardium increases developed force with higher frequencies of stimulation over the frequency range close to the physiological heart rate, showing normal contractile reserve, but failing or dysfunctional myocardium loses this reserve, and therefore FFRs are excellent indicators for evaluating the severity of cardiac contractile dysfunction and cardiac reserve capacity as well as for the evaluation of the effectiveness of therapeutic agents in congestive HF (5). The normal myocardium from sham rat LV muscle strips presented positive FFR as expected (5, 16), whereas the muscle strips from the LV of MCT-treated rats showed overall negative FFR indicative of reduced contractile reserve (5), resembling the hypertrophied RVs of MCT-treated rats in earlier stages of PH (16, 34).

The strong local activation of ET-1 in the LV of MCT-treated rats could straightforwardly lead one to presume that this peptide might be partly underlying the disturbed contractile properties of MCT LV myocardium. Chronic effects of ET-1 without counterregulatory activation of BNP gene expression in the LV of MCT-treated rats, neither myocardial hypertrophy nor fibrosis was observed, underscoring the primordial role of overload on their development (17).

Opposite to BNP and ACE, ET-1 gene expression and peptide production were similar in the RV and LV of MCT-treated rats. Several explanations can be advanced to substantiate the magnitude of LV production of ET-1. First, neurohumoral activation typically accompanies unloading (21), but because neither the LV filling pressures nor LVEDD of MCT-treated rats were lowered and their LV were atrophic, we believe unloading cannot fully explain ET-1 upregulation. Second, some degree of hypoxemia also was acknowledged in MCT-treated rats (23, 37); hence, we studied the mRNA levels of HIF-1α, a central marker of hypoxia-induced ET-1 expression, (15) having observed no differences among groups. Third, various circulating mediators (2, 24) and the sympathetic nervous system (31) are likely inducers of ET-1 gene expression in MCT-treated rats, although their influence would be expected to take place earlier in the development of PH (18). Finally, because ET-1 is an autocrine/paracrine factor in angiotensin II-induced hypertrophy (6, 12), we must point out the possibility that angiotensin II generated by the overactive renopressor and norepinephrine neuronal transporter densities and of norepinephrine neuronal transporter and G protein-coupled receptor kinase activity (18).

Fig. 7. Effects of the selective ETA antagonist BQ-123 on the LV intact muscle strips of sham (n = 7), MCT (n = 7), and MCT+bosentan rats (n = 6). Results are presented as percent % developed tension after BQ-123 treatment. Sham LV muscle strips showed a negative inotropic effect (P = 0.032, as evaluated with paired t-test), whereas the tension developed by MCT and MCT+bosentan muscle strips was unaffected (P = 0.005, as evaluated with one-way ANOVA).
This also was observed in the present study in sham muscle strips. The contractility of LV muscle strips from MCT-treated rats, on the contrary, was unaffected by acute in vitro exposure to BQ-123, which might denote an abnormal functioning of the overactive endothelin system compared with the normal myocardium. Chronic therapy with bosentan did not restore the normal effects of BQ-123 on muscle strips of LV myocardium, but it restored the positivity of FFR compared with MCT-injected PH rats without subsequent treatment with bosentan. Indeed, although bosentan blunted MCT-induced PH as previously reported (9), reducing RV hypertrophy with concomitant attenuation of local neuroendocrine gene expression, the marked change in FFR in the LV of MCT-injected rat myocardium after chronic therapy with bosentan favors the hypothesis of a direct action of chronic ET-1 antagonism on the molecular and functional LV myocardial phenotype. Overall, these results suggest that the beneficial effects of chronic endothelin antagonism in MCT-treated rats (14) may not be dependent exclusively on attenuated PH and improved pulmonary blood flow but also on the myocardial effects of chronic ET-1 blockade.

Despite the similarities with human PH (25), given that MCT-induced PH has no human equivalent, any implication in human pathophysiology is limited. Nevertheless, we must point out that LV myocardial abnormalities may partly underlie LV dysfunction in patients with severe PH (36). Indeed, in patients with PH, normal LV filling is only restored 1 yr after single-lung transplantation even if LV geometry and RV function are immediately restored (36), and combined heart-lung transplantation is favored if severe impairment of LV function is also present because the LV may not recover after transplantation of the lungs alone (27). A patient with severely diminished LV function, however, tolerated double-lung transplantation and fully recovered cardiac function after therapy with bosentan. The authors wisely attributed this to a reduction in ventricular interaction but also admitted that bosentan might have acted directly on the myocardium (1).

In conclusion, MCT-treated rats with severe long-standing PH develop local autocrine/paracrine system activation that is not restricted to the overloaded ventricle. The LV myocardium expresses high levels of genes involved in autocrine/paracrine systems, but despite this, it does not undergo hypertrophy or fibrosis. The LV contractile phenotype, however, is altered: LV muscle strips from MCT-treated rats present negative FFR. Acute ET\textsubscript{A} antagonism in vitro has distinct effects on contractile performance compared with sham myocardium, and chronic ET-1 blockade after MCT injection restores the positivity of LV myocardium FFR, suggesting a possible direct detrimental action of ET-1 overexpression in the LV myocardium of PH rats.

**ACKNOWLEDGMENTS**

We thank the excellent experimental collaboration of Daniel Gonçalves and Antónia Teles, the comments and suggestions of Marc Iglarz of Actelion Pharmaceuticals, and Actelion Pharmaceuticals for the kind gift of bosentan.

**GRANTS**

This work was supported by grants from Fundação para Ciência e Tecnologia (POCI/CBO/47519/2002 and POCI/SAU-MM0/47519/2004; partially funded by FEDER) and from Cardiovascular R&D Unit (51/94-FCT, Portugal).

**REFERENCES**


18. Leineweber K, Brandt K, Wldyba K, Beilfuss A, Pönöcke K, Heinroth-Hoffmann I, and Brodde OE. Ventricular hypertrophy plus neuro-